Corbus Pharmaceuticals Holdings Inc. Stock Falls 7.0%, Underperforms Peers
Dow Jones2026/08/10 20:32This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Corbus Pharmaceuticals Holdings Inc. slid 7.0% to $9.46 on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 0.3% to 26,605.36 and Dow Jones Industrial Average falling 0.1% to 53,975.98.
The stock's fall snapped a four-day winning streak.
Corbus Pharmaceuticals Holdings Inc. closed 54.0% short of its 52-week high of $20.56, which the company achieved on October 20th.
The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. rose 0.4% to $5.02, Fortress Biotech Inc. rose 3.0% to $2.75, and Viking Therapeutics Inc. rose 0.53% to $34.44.
Trading volume totaled 335,566, compared to the 50-day average of 412,692.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 10, 2026 16:32 ET (20:32 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Peter Schiff reiterates the MSTR death spiral theory, claims bitcoin rebound is only temporary
Boliden plans to acquire a 64.7% stake in Nexa Resources (NEXA.US) for $1.31 billion, advancing into the Latin American mining sector.
Boliden AB has signed a final agreement with Votorantim to acquire all of Votorantim's shares in Nexa Resources, thereby obtaining approximately 64.68% of the majority voting rights of this Latin American zinc and silver producer.
Westgold declares FY26 fully franked dividend of 10 cents per share
Crypto prices
More
